Latest news & insights
AMO Pharma announces results of Phase 2 proof-of-concept study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1
AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1 – Patients showed significant improvements
Health & Social Care Select Committee’s report on medicines, devices and substances of human origin has now been published
Back in December, Professor Alan Boyd was invited to appear before the Health & Social Care Select Committee in his capacity as President of the
Evaluation of advanced therapy medicines
The European Medicines Agency (EMA) has updated its procedural advice on the evaluation of advanced therapy medicinal products (ATMPs). The update aims to streamline some
Boyds acquires new Cambridge office to support rapid growth
Boyds is delighted to announce the opening of its new Cambridge office, which has involved an investment in excess of ÂŁ0.5m in the purchase and
European Medicines Agency to move to Amsterdam
Today’s ballot in Brussels, which involved representatives of every EU country (excluding the UK), has resulted in Amsterdam being selected as the new home for
Regulatory Rapporteur
Dr Julie Warner, Director of Regulatory Affairs at Boyds, is also the Associate Editor of TOPRA’s Regulatory Rapporteur journal. In the latest issue, Dr Warner,
FDA approval brings first gene therapy to the United States
The FDA issued a historic action, making the first gene therapy available in the United States, ushering in a new approach to the treatment of
Barriers to orphan drug development
This is the second in a series of articles aiming to highlight the vital role that drug development consultants play in helping small pharma companies